Table 6.
Baseline characteristics and health care exposure of CnsECC.
| Variables | CnsECC n = 150 |
Non-CP-EnsCC n = 86 |
CP-EnsCC n = 64 |
OR (95% CI) |
p |
|---|---|---|---|---|---|
| Sex, female | 62 | 36 | 26 | 0.95 (0.49–1.83) | 0.88 |
| Age (years), median (range) | 68 (4–95) | 70.5 (4–95) | 63 (34–94) | 0.64 | |
| Cardiovascular disease | 105 (70%) | 62 | 43 | 0.79 (0.39–1.60) | 0.52 |
| Cerebrovascular disease | 49 (32.7%) | 26 | 23 | 1.29 (0.65–2.57) | 0.46 |
| Diabetes mellitus | 65 (43.3%) | 35 | 30 | 1.29 (0.67–2.47) | 0.45 |
| Chronic pulmonary disease | 92 (61.3%) | 45 | 47 | 2.51 (1.25–5.06) | 0.01 * |
| Chronic liver disease | 62 (41.3) | 40 | 22 | 0.60 (0.31–1.17) | 0.14 |
| Chronic kidney disease | 94 (62.7) | 55 | 39 | 0.88 (0.45–1.71) | 0.71 |
| Solid tumor | 46 (30.7) | 28 | 18 | 0.81 (0.40–1.65) | 0.56 |
| Hematological malignancies | 48 (32.0) | 27 | 21 | 1.05 (0.65–1.67) | 0.85 |
| Health care exposure (within 3 months) | |||||
| Indwelling devices | 138 (92) | 78 | 60 | 1.54 (0.44–5.39) | 0.50 |
| Hemodialysis | 26 (17.3) | 14 | 12 | 1.18 (0.51–2.78) | 0.69 |
| Ventilator support | 93 (62) | 40 | 53 | 5.54 (2.55–12.03) | <0.001 * |
| Surgery | 63 (42) | 36 | 27 | 1.01 (0.53–1.96) | 0.97 |
| Chemotherapy | 12 (8) | 6 | 6 | 1.38 (0.42–4.49) | 0.59 |
| Steroid exposure | 53 (35.8) | 19 | 34 | 3.88 (1.91–7.88) | <0.001 * |
| Antibiotics exposure | 147 (98) | 83 | 64 | 5.41 (0.27–106.6) | 0.27 |
| Carbapenems exposure | 57 (38) | 25 | 31 | 2.17 (1.10–4.25) | 0.02 * |
Abbreviations: CnsECC, Carbapenem-nonsusceptible Enterobacter cloacae complex; CP, carbapenemase-producing. * Statistical significance, p < 0.05.